

Aspirin use doesn't cut cancer incidence in older T2DM patients

June 25 2018



(HealthDay)—For Japanese patients with type 2 diabetes, low-dose

aspirin is not associated with reduced cancer incidence, except in those younger than 65 years, according to a study published online June 16 in *Diabetes Care*.

Sadanori Okada, M.D., from Nara Medical University in Kashihara, Japan, and colleagues conducted a post-trial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial. A total of 2,536 patients with type 2 [diabetes](#) were randomized to receive [aspirin](#) (81 or 100 mg daily) or no aspirin. Participants were followed from the trial end in 2008 until 2015.

The researchers found that 318 cancers occurred during a median follow-up of 10.7 years. There was no significant difference between the aspirin and no-aspirin groups in terms of [cancer](#) incidence (hazard ratio, 0.92; 95 percent confidence interval, 0.73 to 1.14; P = 0.4). Aspirin did not affect cancer incidence in men, women, or those aged ≥ 65 years in subgroup analyses. There was a decrease in cancer incidence associated with aspirin use among those aged

Citation: Aspirin use doesn't cut cancer incidence in older T2DM patients (2018, June 25)
retrieved 4 May 2024 from

<https://medicalxpress.com/news/2018-06-aspirin-doesnt-cancer-incidence-older.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--